Aarti Pharmalabs Limited

rs,

September 14, 2023 To, Listing/ Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 SCRIP CODE: 543748 Dear Sir/Madam, To, Listing/ Compliance De

59%

h proximity to ports ▪ Largest Indian Manufacturer for Xanthine Derivatives (Caffeine and Others) 59% 55% 45% 41% Key Metrics Financial Highlights 150+ Products 500+ Global Customers 40 USDMF 20

55%

oximity to ports ▪ Largest Indian Manufacturer for Xanthine Derivatives (Caffeine and Others) 59% 55% 45% 41% Key Metrics Financial Highlights 150+ Products 500+ Global Customers 40 USDMF 20 CEP

45%

ty to ports ▪ Largest Indian Manufacturer for Xanthine Derivatives (Caffeine and Others) 59% 55% 45% 41% Key Metrics Financial Highlights 150+ Products 500+ Global Customers 40 USDMF 20 CEP 52+

41%

ports ▪ Largest Indian Manufacturer for Xanthine Derivatives (Caffeine and Others) 59% 55% 45% 41% Key Metrics Financial Highlights 150+ Products 500+ Global Customers 40 USDMF 20 CEP 52+ pat

rs 40

nd Others) 59% 55% 45% 41% Key Metrics Financial Highlights 150+ Products 500+ Global Customers 40 USDMF 20 CEP 52+ patents files 193 1431 0.12 6 Manufacturing Units 3 USFDA Units 2000+ Emp

rs. 4

lidated PAT Consolidated Fixed Assets Gross Block Net Debt to Equity 3 R&D Centres Amt in Rs Crs. 4 4 Journey Incorporated Aarti organic Private Limited Commissioning of first API manufacturing

100 MT

EUGMP approval for Bicalutamide •Unit 5 commissioned for Caffeine Production with a capacity of 100 MT per month •Unit 4 clears USFDA audit for the 3rd time Oncology block at Unit 4 audited by EDQ

53%

manufacturing facility ❏ Exports to lucrative regulated markets - US, EU and Japan contributes to 53% of total exports. ❏ Backward integrated intermediates for most APIs ❏ Distinct advantage having

5000 MT

of asthma or influenza symptoms • 2 dedicated manufacturing units • Aggregate Capacities of about 5000 MTA for Xanthine Derivatives. • One backward integrated unit for providing KSM for Xanthine deri

20%

• One backward integrated unit for providing KSM for Xanthine derivatives. • APL has about 15-20% Global Market Share Cola Drinks Energy Drinks Pharmaceutic als Nutraceutical s • Sole Non i

INR 1945

mance ……………………………………………….. 12 FY23 : Important Numbers (Consolidated) Revenue from operations INR 1945 crs EBITDA INR 344 crs PAT EPS Highlights of Q4 FY 24 Net worth INR 1558 crs Net Debt to Equ

Location

1

Location

Dombivali Unit - II Custom synthesis division (CSD) Location: Vapi R&D Centers Location: Vapi, Dombivali Vap i Dombiva li Maharasht ra Head Office API, Intermediates & CDMO Facility Xanthine Derivatives Manufacturing Facility Upcoming Manufacturing Facility Product development & Technology Transfer 6 Key Business Verticals APIs and Intermediates CDMO / CMO Services ❏ US FDA approved manufacturing facility ❏ Exports to lucrative regulated markets - US, EU and Japan contributes to 53% of total exports. ❏ Backward integrated intermediates for most APIs ❏ Distinct advantage having dedicated USA, Japan and EU approvals ❏ Dedicated blocks for Anti-Cancer and Cortico Steroids products ❏ HPAPIs development and manufacturing ❏ Flow chemistry from lab to manufacturing ❏ Complete CMC documentation support ❏ CRAMs activity intermediates focused on API & ❏ Working with 14 Innovators & Big Pharma companies Xanthine derivatives & Allied (Caffeine and others) ❏ Largest Indian Manufacturer for (Caffein